期刊文献+

阻断泛素-蛋白酶体通路对食管癌细胞生长及端粒酶活性的影响 被引量:2

Effect of inhibited ubiquitin-proteasome pathway on growth and activity of telomerase in esophageal carcinoma cells
暂未订购
导出
摘要 目的 :研究阻断泛素 -蛋白酶体通路对食管癌细胞生长及端粒酶活性的影响。方法 :将不同浓度的MG - 132加入食管癌细胞株Eca970 6 ,特异性阻断其泛素 -蛋白酶体通路 ,用四甲基偶氮唑蓝 (MTT)法测定细胞生长抑制效应 ,显微镜下观察细胞形态变化 ,流式细胞仪 (FCM)检测细胞周期及凋亡 ,DNA片段分析进一步证实凋亡的存在 ,并对端粒酶的活性进行检测。结果 :MG - 132对食管癌细胞株Eca970 6有显著的生长抑制作用 ,且呈现剂量与时间的依赖性 ,显微镜下可见明显的细胞病变 ,细胞变圆、变小、脱落 ,FCM显示MG - 132作用于食管癌细胞后 ,G1期比例增加 ,并有明显的亚二倍体凋亡峰 ,细胞DNA抽提电泳后发现凋亡特征性梯状条带 ,端粒酶的活性显著受抑制。结论 :MG - 132能显著抑制食管癌细胞株Eca970 6的生长 ,并抑制端粒酶的活性 ,表明阻断泛素 AIM: To investigate the effect on growth and activity of telomerase in esophageal carcinoma cells by inhibiting ubiquitin-proteasome pathway(UPP). METHODS: The esophageal carcinoma cell strain Eca9706 was treated with MG-132 to inhibit its UPP specially. The effect of growth suppression on cells was evaluated with MTT assay, morphologic changes of cells were observed under microscope, cell cycle and apoptosis were detected by flow cytometry (FCM). DNA fragment analysis was used to confirm the presence of apoptosis. The activity of telomerase was detected. RESULTS: MG-132 had obvious inhibitory effect on the growth of Eca9706 cells in a dose and time-dependent manner. Obvious pathologic change of cells were observed under microscope, cells became round, small and exfoliating. The FCM analysis showed that the ratio of esophageal carcinoma cells of G_1 phase increased and a obviously apoptotic sub-G_1 peak was found. Agarose electrophoresis showed marked ladder. The activity of telomerase was obviously inhibited. CONCLUSIONS: MG-132 significantly inhibits the growth and the activity of telomerase of Eca 9706 cells. These findings indicate that inhibiting UPP is a new strategy for the treatment of esophageal carcinoma. [
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2004年第7期1208-1212,共5页 Chinese Journal of Pathophysiology
基金 本院重点科研资助课题
关键词 泛素-蛋白酶体 食管肿瘤 细胞周期 细胞凋亡 端粒 末端转移酶 Ubiquitin-proteasome Esophageal neoplasms Cell cycle Apoptosis Telomerase
  • 相关文献

参考文献16

  • 1[1]King RW, Deshaies RJ, Peters JM, et al. How proteolysis drives the cell cycle[J]. Science, 1996, 274 (5293): 1652- 1659.
  • 2[2]Bacinaga M. A new twist to the cell cycle[J]. Science,1995,269(5224) :631 - 632.
  • 3[3]Lim MS, Adamson A, Lin Z, et al. Expression of Skp2, a p27(Kip1) ubiquitin ligase, in malignant lymphoma: correlation with p27(Kip1) and proliferation index[J]. Blood, 2002,100(8) :2950 - 2956.
  • 4[4]Li M, Chen D, Shiloh A, et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization[J]. Nature, 2002, 416(6881):648-653.
  • 5倪晓华,华富勇,曹根涛.端粒酶活性与慢性粒细胞白血病病程关系的研究[J].中国病理生理杂志,2000,16(5):454-456. 被引量:4
  • 6李文瑜,张洹.hTERT基因反义核酸对Jurkat细胞端粒酶活性影响[J].中国病理生理杂志,2002,18(1):4-7. 被引量:16
  • 7[7]Sun J, Nam S, Lee CS, et al. CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A- 549 in nude mice[J]. Cancer Res, 2001, 61(4): 1280 - 1284.
  • 8[8]Marshansky V, Wang X, Bertrand R, et al. Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl - 2 family members and compromise functioning of the electron transport chain in leukemic cells[J]. J Immunol, 2001, 166 (5) :3130- 3142.
  • 9[9]LeBlanc R, Cadey LP, Hideshima T, et al. Proteasome inhibitor PS - 341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model [ J ]. Cancer Res,2002, 62(17) :4996 - 5000.
  • 10[10]Hochwald SN, Lind DS, Malaty J, et al. Antineoplastic therapy in colorectal cancer through proteasome inhibition[J]. Am Surg, 2003, 69(1):15-23.

二级参考文献13

共引文献18

同被引文献23

  • 1蔡同建,陈景元,李妍,季爱玲,杜可军,骆文静.蛋白酶体抑制剂MG132对PC12细胞的增殖抑制作用[J].第四军医大学学报,2006,27(12):1137-1139. 被引量:5
  • 2Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B -cell non- Hodgkin's lymphoma [ J ]. J Clin Oncol, 2005,23 (4) : 667 -675.
  • 3Lee J, Suh C, Kang HJ, et al. Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T - cell or NK - T - cell lymphoma[ J]. Annals Oncol,2008,19(12) : 2079 - 2083.
  • 4Su ZL, Mo XL, Feng ZY, et al. UBE1 expression in extranodal NK/T cell lymphoma, nasal type[ J]. Leuk Lymphoma, 2008,49(9) : 1821 - 1822.
  • 5Kagami Y, Nakamura S, Suzuki R,et al. Establishment of an IL -2 - dependent cell line derived from 'nasal - type' NK/T- cell lymphoma of CD2^+ , sCD3^-, CD3 epsilon+, CD56^+ phenotype and associated with the Epstein - Barr virus[J]. Br J Haematol, 1998, 103(3) : 669 -677.
  • 6Kim GE, Cho JH, Yang WI, et al. Angiocentric lymphoma of the head and neck : patterns of systemic failure after radiation treatment[ J]. J Clin Oncol, 2000, 18 (1): 54 - 63.
  • 7Mo XL, Su ZL, He D, et al. Skp2/p27 expression profile is correlated with Epstein - Barr virus status in extranodal nasal- type natural killer cell lymphoma [ J ]. Transpl Res, 2008, 151(6): 303-308.
  • 8Mo XL, Su ZL, Zheng FC, et al. Suppression of EBNAI expression inhibits growth of EBV - positive NK/T cell lymphoma cells [ J ]. Cancer Biol Ther, 2008,7 ( 10 ) : 1602 - 1606.
  • 9Mani A, Gelmann EP. The ubiquitin -proteasome pathway and its role in cancer [ J ]. J Clin Oncol, 2005,23 (21) : 4776-4789.
  • 10He Q, Huang Y, Sheikh MS. Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax -proficient and - deficient ceils [ J ]. Oncogene, 2004, 23 (14) : 2554 - 2558.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部